This article complements other eligibility and science-focused pieces by walking through real-world timelines—from first injections to diagnosis—and how lawyers piece together those dates when evaluating Depo-Provera cases.
If you've used Depo-Provera and have been diagnosed with a meningioma, you may be wondering how long it takes for these brain tumors to develop after using the medication. Understanding the timeline between Depo-Provera exposure and meningioma diagnosis is important for understanding your potential legal rights and whether you may have a valid claim.
Recent research has revealed a connection between long-term Depo-Provera use and the development of meningiomas, tumors that form on the protective layers surrounding the brain and spinal cord. A landmark French study found that women who used high-dose progestogen medications like Depo-Provera for extended periods faced significantly elevated risks of developing these tumors. This guide will help you understand the timeline for meningioma development and what factors may affect when symptoms appear.
Pharmaceutical products and medical research documents
Understanding Meningioma Development Timeline
The timeline for meningioma development after Depo-Provera exposure is complex and varies from person to person. Meningiomas are typically slow-growing tumors that develop gradually over time, which means symptoms may not appear immediately after exposure begins. The research suggests that the risk increases with the duration of Depo-Provera use, indicating that cumulative exposure over time plays a significant role in tumor development.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Studies have found that women who used Depo-Provera for extended periods, particularly five or more years, face significantly higher risks of developing meningiomas. This suggests that the tumors may develop gradually over the course of years of medication use, rather than appearing immediately after starting the injections. The cumulative nature of the exposure means that each injection adds to the overall risk, with longer use periods associated with higher risk levels.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationIt's important to understand that meningiomas can develop at different rates, and symptoms may not appear until the tumor reaches a certain size or affects specific areas of the brain. Some women may develop symptoms relatively quickly after years of use, while others may not experience symptoms until many years later. The variability in development timeline makes it important to monitor your health if you've used Depo-Provera for extended periods.
What Are Meningiomas?
Meningiomas are tumors that form on the meninges, the protective layers surrounding the brain and spinal cord. While typically non-cancerous, they can cause serious symptoms as they grow. These tumors develop from cells in the meninges and can vary in size and location, which affects both symptoms and treatment options.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Common symptoms of meningiomas include persistent headaches, vision problems, hearing loss or ringing in ears, memory difficulties, seizures, weakness in limbs, and personality changes. The severity of symptoms often depends on the size and location of the tumor. Some meningiomas may cause no symptoms and are discovered incidentally during imaging for other conditions, while others can lead to significant neurological problems requiring immediate treatment.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Meningiomas are the most common type of primary brain tumor, accounting for approximately one-third of all brain tumors. While most are benign, they can still cause serious health issues depending on their location and size. Treatment options may include monitoring, surgery, radiation therapy, or a combination of approaches depending on the individual case.
Factors Affecting Development Timeline
Several factors may affect how long it takes for meningiomas to develop after Depo-Provera exposure. Understanding these factors can help you better understand your individual situation and potential risks.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewDuration of Use: Research suggests that the risk of developing meningiomas increases with the duration of Depo-Provera use. Women who used the medication for extended periods, particularly five or more years, may face significantly higher risks. The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Cumulative Exposure: The cumulative nature of Depo-Provera exposure means that each injection adds to the overall hormone levels in the body. Women who received injections for many years may have had significantly higher cumulative exposure than those who used the medication for shorter periods. This cumulative exposure may contribute to the gradual development of meningiomas over time.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Individual Factors: Individual factors such as age, genetics, and overall health may also play a role in how quickly meningiomas develop. Some women may be more susceptible to the effects of progestogen exposure than others, which could affect the timeline for tumor development.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Tumor Location and Size: The location and size of the meningioma can affect when symptoms appear. Tumors in certain areas of the brain may cause symptoms more quickly, while others may grow for years before causing noticeable problems. This variability can make it difficult to determine exactly when a tumor began developing.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, you may want to learn more about Depo-Provera lawsuit information and your potential rights.
Legal documents and research papers representing ongoing litigation
Research on Development Timeline
The scientific research linking Depo-Provera to meningiomas is still evolving, and specific timelines for tumor development are not yet fully established. However, the available evidence suggests that the risk increases with the duration of medication use, indicating that tumors may develop gradually over years of exposure.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The landmark French study published in the BMJ examined medical records of thousands of women and found a significant association between long-term use of high-dose progestogen medications, including Depo-Provera, and the development of meningiomas. The study found that women who used Depo-Provera for extended periods faced substantially higher risks compared to women who did not use the medication.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The research suggests that the hormone medroxyprogesterone acetate, the active ingredient in Depo-Provera, may play a role in the development of these tumors over time. While the exact mechanism is still being studied, the evidence indicates a clear association between long-term Depo-Provera use and increased meningioma risk that appears to develop gradually with cumulative exposure.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitWhat Is Depo-Provera?
Depo-Provera is an injectable contraceptive medication that contains the hormone medroxyprogesterone acetate. The medication is administered as an injection every three months to prevent pregnancy. It has been used by millions of women worldwide since its approval by the FDA in 1992.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The medication works by preventing ovulation and thickening cervical mucus to block sperm. While effective for birth control, emerging research has raised concerns about potential long-term health risks, particularly related to brain tumor development. Many women have used Depo-Provera for extended periods, sometimes for years or even decades, which may have contributed to the increased risk observed in recent studies.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewDepo-Provera injections are typically administered by healthcare providers into the muscle of the arm or buttock. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness for approximately 12 to 14 weeks. The cumulative exposure from repeated injections over many years may be a factor in the increased meningioma risk observed in long-term users.
How Exposure Occurred
Women were exposed to Depo-Provera through regular injections administered by healthcare providers. The medication is typically injected into the muscle of the arm or buttock every 12 to 14 weeks. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Exposure occurred through regular injections every three months, long-term use over multiple years, cumulative exposure building up over time, and direct injection into muscle tissue. Many women used Depo-Provera for extended periods, sometimes for years or even decades. This long-term, repeated exposure may have contributed to the increased risk of developing meningiomas observed in recent studies.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The cumulative nature of the exposure is particularly important when considering development timelines. The hormone builds up in the body over time with each injection, and women who received injections for many years may have had significantly higher cumulative exposure than those who used the medication for shorter periods. This cumulative exposure may explain why the risk increases with duration of use and why tumors may develop gradually over time.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibility
Evidence and documents in legal proceedings
Who May Be Affected
Women who used Depo-Provera for extended periods may be at increased risk of developing meningiomas. Research suggests that the risk increases with the duration of use. Women who used the medication for one to four years may face a moderate increase in risk, while those who used it for five or more years may face significantly higher risks. Women who used it for ten or more years may face the highest risks.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users. Women who have been diagnosed with meningiomas after using Depo-Provera should consider having their situation evaluated to determine whether they may have a valid legal claim.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe timeline for meningioma development can vary, and symptoms may appear at different times for different women. Some may develop symptoms relatively quickly after years of use, while others may not experience symptoms until many years later. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, regardless of when symptoms appeared, you may want to learn more about Depo-Provera lawsuit information and your potential rights.
Current Status of Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development, and this evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
Evidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
What a Case Review Involves
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitA case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced. The timeline between your medication use and diagnosis may be an important factor in evaluating your potential claim.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have that shows the duration of your use.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis relative to your medication use, and how your case fits within the broader litigation.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Why timing and records matter
Pharmacy records, injection dates, and radiology reports anchor most screenings. Gather them before your consultation so attorneys spend time on strategy—not chasing basic documents.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Scientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Litigation Timeline: Mass tort litigation typically takes several years to resolve. Cases may proceed through discovery, expert witness preparation, and potentially trials or settlement negotiations. The timeline for your specific case depends on many factors beyond your control.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Important Disclaimers
The timeline for meningioma development after Depo-Provera exposure can vary significantly from person to person. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is an important first step, regardless of when your symptoms appeared.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Preserving medical records, pharmacy histories, and work exposure logs now can make a later evaluation smoother—even if you are still deciding whether to pursue a claim.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
